FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

L								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Instruction 1(b).		Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934										
			or Section 30(h) of the Investment Company Act of 1940										
1. Name and Address of Reporting Person* PERRY MICHAEL S (Last) (First) 177 E. COLORADO BLVD			2. Issuer Name and Ticker or Trading Symbol <u>ARROWHEAD PHARMACEUTICALS,</u> <u>INC.</u> [ARWR] 3. Date of Earliest Transaction (Month/Day/Year) 01/01/2021		ationship of Re k all applicable Director Officer (give below))	on(s) to Issuer 10% Owner Other (specify below)						
SUITE 700			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	vidual or Joint/	Group Filing ((Check Applicable						
(Street)				Line)									
PASADENA	СА	91105		X	Form filed b	y One Report	ting Person						
					Form filed b Person	y More than (One Reporting						
(City)	(State)	(Zip)											

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following	Form: Direct	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	- Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	01/01/2021		A		9,000(1)	A	\$0.00	94,000	D	
Common Stock Sold	01/04/2021		S		4,000	D	\$76.09 ⁽²⁾	90,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(371	,	,		,	• /				,			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) of Dispo of (D) (Instr	Derivative (Month/Day/Year) Securities Acquired (A) or Disposed		Expiration Date Amount of			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

2. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$76.06 to \$76.33, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Remarks:

/s/Michael Perry

** Signature of Reporting Person

01/05/2021 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.